Cardinal Health, Inc.
Cardinal Health, Inc. (CAH) is a major US healthcare services and products company, with a market capitalisation near $37.7 billion. It operates large-scale pharmaceutical distribution and supplies medical-surgical products to hospitals, pharmacies and clinics, while also developing higher‑margin device and services offerings. Investors should know the business combines high-volume, low-margin distribution with targeted growth in medical products, so operational efficiency, inventory management and contract terms are key profit levers. The company faces sector-specific risks including reimbursement pressure, hospital budget cycles, regulatory scrutiny and strong competition from peers. Recent strategic emphasis has been on margin improvement, specialty products and supply-chain resilience, though execution and healthcare demand trends will matter. This is general educational information, not personalised advice; values can rise or fall and past performance is no guarantee of future results. Consider how exposure to healthcare distribution fits your risk tolerance and investment horizon before acting.
Why It's Moving
Cardinal Health Stock Hovers Near 52-Week Highs as Analysts Signal Caution Despite Strong Earnings
- Q2 earnings beat expectations by $0.32 per share ($2.63 actual vs. $2.31 consensus), with revenue surpassing forecasts and year-over-year growth of 18.8%, bolstering the company's raised full-year guidance of $10.15–$10.35 in adjusted EPS
- The stock is trading near its 52-week high of $233.60 and above both its 50-day and 200-day moving averages, but an RSI of 86.05 indicates overbought conditions that could trigger profit-taking or short-term volatility
- Analyst consensus remains strongly bullish with 13 buy ratings and no sell ratings, though average price targets of $245–$249 suggest only 11–14% upside from current levels, potentially explaining analyst caution on near-term momentum
Cardinal Health Stock Hovers Near 52-Week Highs as Analysts Signal Caution Despite Strong Earnings
- Q2 earnings beat expectations by $0.32 per share ($2.63 actual vs. $2.31 consensus), with revenue surpassing forecasts and year-over-year growth of 18.8%, bolstering the company's raised full-year guidance of $10.15–$10.35 in adjusted EPS
- The stock is trading near its 52-week high of $233.60 and above both its 50-day and 200-day moving averages, but an RSI of 86.05 indicates overbought conditions that could trigger profit-taking or short-term volatility
- Analyst consensus remains strongly bullish with 13 buy ratings and no sell ratings, though average price targets of $245–$249 suggest only 11–14% upside from current levels, potentially explaining analyst caution on near-term momentum
When is the next earnings date for Cardinal Health, Inc. (CAH)?
Cardinal Health (CAH) is estimated to announce its next earnings report between April 29-30, 2026, with the most commonly cited date being April 30, 2026. This earnings release will cover the company's Q3 FY2026 results and will be accompanied by a conference call for investors. Based on historical patterns, the announcement is expected to occur either before market open or after market close. Analysts are currently forecasting earnings per share of approximately $2.80 for this quarter.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Cardinal Health's stock with a target price of $220.6, indicating growth potential.
Financial Health
Cardinal Health is generating steady revenue and cash flow, but its profit margins are low.
Dividend
Cardinal Health's low dividend yield of 0.94% means it’s not a strong choice for dividend income. If you invested $1000 you would be paid $9.40 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CAH
Pharmaceutical Policy Shift Explained | Pricing Models
The Trump administration's recent drug pricing agreements with major pharmaceutical companies like AstraZeneca and Pfizer aim to lower U.S. drug costs by tying them to international prices. This creates a potential investment opportunity in pharmaceutical firms with strong domestic production and those in the healthcare supply chain that can adapt to the new pricing landscape.
Published: October 12, 2025
Explore BasketDomestic Pharma Tariffs: What's Next for Investors
The U.S. government has imposed a 100% tariff on pharmaceuticals from companies lacking domestic manufacturing, aiming to reshore production. This policy creates a significant advantage for U.S.-based pharmaceutical companies and their supply chains, which are poised for growth as reliance on imports decreases.
Published: September 26, 2025
Explore BasketWalgreens Restructuring Explained: Investment Shifts
Following its acquisition by Sycamore Partners, Walgreens has gone private and split into five companies. This theme explores the investment opportunities created by the newly independent healthcare and retail entities.
Published: September 2, 2025
Explore BasketWalgreens' Restructuring: A New Healthcare Landscape
Following its $10 billion acquisition by Sycamore Partners, Walgreens is going private and splitting into five separate companies. This major restructuring of a key industry player could create significant opportunities for competitors and specialized healthcare service providers to capture market share.
Published: August 29, 2025
Explore BasketNavigating U.S. Drug Price Reforms
The White House is demanding major pharmaceutical companies slash U.S. drug prices, creating significant market volatility and threatening industry profits. This creates a potential opening for companies that offer cost-saving alternatives, such as generic drug makers and healthcare service providers.
Published: August 5, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Scale & Distribution
A wide distribution network underpins revenue through volume, but margins are typically thin so operational efficiency is essential.
Higher‑Margin Push
Growth in medical devices and services aims to lift margins, though execution risk and competitor response are important considerations.
Regulation & Cycles
Reimbursement trends, hospital spending cycles and regulatory changes can materially affect performance, and returns may vary over time.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Amgen Inc.
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc. is an integrated generic and specialty pharmaceutical company that develops, manufactures, and markets generic and specialty pharmaceutical products.
